Pancreatic Cancer Research

ResearcherGeorgetown UniversityActive in the last 2 years

Eveline E. Vietsch

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0631-4484; OpenAlex author ID A5037891710. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 4 papers · 2022: 3 papers · 2023: 1 paper · 2024: 2 papers

Papers 16

  1. FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction. Co-author DOI 10.1016/j.ejca.2023.113440↗
  2. The tumor immune microenvironment in resected treatment-naive pancreatic cancer patients with long-term survival. Co-author DOI 10.1016/j.pan.2024.08.014↗
  3. B cell immune profiles in dysbiotic vermiform appendixes of pancreatic cancer patients. Co-author DOI 10.3389/fimmu.2023.1230306↗
  4. Impaired CXCL12 signaling contributes to resistance of pancreatic cancer subpopulations to T cell-mediated cytotoxicity. Co-author DOI 10.1080/2162402x.2022.2027136↗
  5. Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients. Co-author DOI 10.3389/fimmu.2022.898498↗
  6. Distinct Response of Circulating microRNAs to the Treatment of Pancreatic Cancer Xenografts with FGFR and ALK Kinase Inhibitors. First author DOI 10.3390/cancers14061517↗
  7. Circulating Immunological Biomarkers: Prognosis of Pancreatic Cancer Patients Reflected by the Immune System. Co-author DOI 10.1097/mpa.0000000000001862↗
  8. Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1681↗
  9. Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. Co-author DOI 10.1177/17588359211033704↗
  10. Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicente… Last author DOI 10.3390/ijms222010902↗
  11. Serum miR-338-3p and miR-199b-5p are associated with the absolute neutrophil count in patients with resectable pancreatic cancer. First author DOI 10.1016/j.cca.2020.03.005↗
  12. Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection. Co-author DOI 10.3390/app9224784↗
  13. Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. First author DOI 10.3390/cancers11010093↗
  14. Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Co-author DOI 10.1016/j.cancergen.2018.11.001↗
  15. Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Co-author DOI 10.1016/j.cancergen.2017.08.006↗
  16. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Co-author DOI 10.1126/scisignal.2005049↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Casper H.J. van Eijck · 11 shared papers, 2019–2024 · strength 1.53
  2. Fleur van der Sijde · 9 shared papers, 2019–2024 · strength 1.21
  3. Dana A. M. Mustafa · 7 shared papers, 2019–2024 · strength 0.98
  4. Bas Groot Koerkamp · 7 shared papers, 2019–2024 · strength 0.90
  5. Anton Wellstein · 6 shared papers, 2014–2022 · strength 0.67
  6. Marc G. Besselink · 4 shared papers, 2019–2022 · strength 0.45
  7. Casper W.F. van Eijck · 2 shared papers, 2024 · strength 0.39
  8. Marcella Willemsen · 2 shared papers, 2023–2024 · strength 0.35
  9. Johanna W. Wilmink · 3 shared papers, 2021–2022 · strength 0.34
  10. Brigitte C.M. Haberkorn · 3 shared papers, 2021–2022 · strength 0.34
  11. Marjolein Y.V. Homs · 3 shared papers, 2021–2022 · strength 0.34
  12. Yunlei Li · 2 shared papers, 2020–2024 · strength 0.33
  13. Peter D. Katsikis · 2 shared papers, 2021–2023 · strength 0.31
  14. Freek R. van ‘t Land · 2 shared papers, 2021–2024 · strength 0.31
  15. Ivana Peran · 2 shared papers, 2019–2022 · strength 0.30
  16. Quisette P. Janssen · 2 shared papers, 2021–2022 · strength 0.23
  17. Bert A. Bonsing · 2 shared papers, 2021 · strength 0.21
  18. Gaby J. Strijk · 1 shared paper, 2024 · strength 0.21
  19. Lara Rosaline Heij · 1 shared paper, 2024 · strength 0.18
  20. Georg J. Wiltberger · 1 shared paper, 2024 · strength 0.18
  21. Núria Malats Riera · 1 shared paper, 2024 · strength 0.18
  22. Giuseppe Giaccone · 2 shared papers, 2017–2018 · strength 0.17
  23. John Lindsay Marshall · 2 shared papers, 2017–2018 · strength 0.17
  24. Yuan-Na Lin · 1 shared paper, 2022 · strength 0.16
  25. Noel F.C.C. de Miranda · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.